GlassScriptPhysician profile
Brian P Singeltary
NPI 1972890895
$790.83
in general payments reported to CMS, 2019-2025
19 companies · $278 in 2025
The $278 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.04 · 2021: $15.72 · 2022: $15.80 · 2023: $176 · 2024: $286 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $723 · Education: $16.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $722.70 |
| Education | $16.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $179.31 | 2022-2025 | |
| Pfizer INC. | $111.47 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $90.36 | 2023-2025 | Enhertu |
| Gilead Sciences, INC. | $47.22 | 2024-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $42.08 | 2024 | Ojjaara |
| Servier Pharmaceuticals LLC | $39.94 | 2023 | |
| Sirtex Medical INC | $36.08 | 2024-2025 | Sir-Spheres Microspheres |
| Aveo Pharmaceuticals, INC. | $35.26 | 2024 | |
| Morphosys, US INC. | $24.29 | 2023 | Monjuvi |
| Genzyme Corporation | $21.34 | 2024 | |
| Incyte Corporation | $21.16 | 2023 | Pemazyre, Monjuvi |
| Abbvie INC. | $21.15 | 2025 | |
| Astellas Pharma US INC | $20.04 | 2020 | |
| Pharmaessentia USA Corporation | $19.15 | 2023 | Besremi |
| Merck Sharp & Dohme LLC | $18.54 | 2024 | Lynparza, Keytruda |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $16.64 | 2025 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $16.57 | 2023 | Opdivo |
| Amgen INC. | $15.72 | 2021 | |
| Agios Pharmaceuticals, INC. | $14.51 | 2025 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Singeltary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.